Drugs--Federal Drug Administration Ban on Laetrile Treatments for Terminally Ill Cancer Patients is Arbitrary and Capricious by Bitting, Terry Horwath
Tulsa Law Review 
Volume 14 Issue 1 
1978 
Drugs--Federal Drug Administration Ban on Laetrile Treatments 
for Terminally Ill Cancer Patients is Arbitrary and Capricious 
Terry Horwath Bitting 
Follow this and additional works at: https://digitalcommons.law.utulsa.edu/tlr 
 Part of the Law Commons 
Recommended Citation 
Terry H. Bitting, Drugs--Federal Drug Administration Ban on Laetrile Treatments for Terminally Ill Cancer 
Patients is Arbitrary and Capricious, 14 Tulsa L. J. 222 (2013). 
Available at: https://digitalcommons.law.utulsa.edu/tlr/vol14/iss1/9 
This Casenote/Comment is brought to you for free and open access by TU Law Digital Commons. It has been 
accepted for inclusion in Tulsa Law Review by an authorized editor of TU Law Digital Commons. For more 
information, please contact megan-donald@utulsa.edu. 
RECENT DEVELOPMENT
DRUGS-FEDERAL DRUG ADMINISTRATION BAN ON LAETRILE
TREATMENTS FOR TERMINALLY ILL CANCER PATIENTS Is ARBI-
TRARY AND CAPRICIOUS. Rutherford v. United States, 582 F.2d
1234 (10th Cir. 1978).
In Rutherford v. United States,' the Court of Appeals from the
Tenth Circuit held that terminally ill cancer patients may receive treat-
ments of laetrile despite the prohibition of the drug by the Food and
Drug Administration (FDA). This decision overturned an earlier rul-
ing by the FDA Commissioner that laetrile2 was a new drug' within the
meaning of the Federal Food, Drug and Cosmetic Act (FFDC Act).4
As a new drug, laetrile had not been determined by the FDA to be
generally recognized by qualified experts as safe and effective.5 There-
fore, its distribution had been banned by the agency.6
1. 582 F.2d 1234 (10th Cir. 1978), a f'g 399 F. Supp. 1208 (W.D. Okla. 1975), cerl. granted
47 U.S.L.W. 3492 (U.S. Jan. 23, 1979)(No. 78-605).
2. "Laetrile is the name of a product whose major component or ingredient is the chemical
amygdalin, a substance that occurs naturally in the pits of apricots, peaches, bitter almonds, and in
other plant material." 42 Fed. Reg. 10,066 (1977).
3. The Federal, Food, Drug and Cosmetic (FFD) Act of 1928, 21 U.S.C. §§ 301-392
(1976), defines a new drug as:
(I) Any drug... the composition of which is such that such drug is not generally
recognized, among experts qualified by scientific training and experience to evaluate the
safety and effectveness of drugs, as safe and eeclive for use under the conditions pre-
scribed, recommended, or suggested in the labeling thereof,. . . or (2) any drug.., the
composition of which is such that such drug, as a result of investigations to determine its
safety and efectiveness for use under such conditions, has become so recognized, but
which has not, otherwise than in such investigations, been used to a material extent or
for a material time under such conditions.
21 U.S.C. §321(p) (1976) (1962 amendments in italics). The 1962 amendments added the addi-
tional requirement that a new drug be effective as well as safe.
A drug could avoid a new drug classification under the grandfather clause of the FFDC Act,
if on October 9, 1962: (1) the drug was commercially used or sold in the United States; (2) it was
not a new drug pursuant to 21 U.S.C. §321(p) of the Food and Drugs Act then in force, which
required that only the safe test be met; and (3) it was not covered by an effective new drug applica-
tion; and (4) its labeling contained the same representations concerning the conditions of its use.
4. 21 U.S.C. §§301-392 (1976).
5. 42 Fed. Reg. 39,768 (1977). Moreover, the Commissioner concluded that laetrile was not
exempt under the grandfather provisions of the FFDC Act. Id. at 39,787-91.
6. The FDA derives its authority to regulate drugs in interstate commerce pursuant to 21
U.S.C. §244(a) (1972) which states that "no person shall introduce or deliver for introduction into
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In 1975, a class action was brought on behalf of cancer patients
and their spouses to enjoin the FDA from interfering with the distribu-
tion of laetrile7 The trial court reviewed the administrative record and
concluded that the FDA's classification of laetrile as a new drug8 was
unsupported by substantial evidence.9 On this finding, the court ruled
that the agency's action was arbitrary and capricious."0 Further, it held
that the provisions of the FFDC Act were violative of a cancer patient's
constitutionally protected right of privacy, here the right to use a non-
toxic substance." The district court enjoined the FDA from preventing
the plaintiffs' importation and interstate transportation of laetrile for
their own consumption, until there was substantial evidence to support
the FDA's determination.12
On appeal, the Tenth Circuit affirmed the lower court's decision. 3
It found that the FDA had not advanced any standard against which
the safety and effectiveness of laetrile as a treatment for terminally ill
cancer patients could be judged.'4 Absent such a standard, the court of
appeals held that the safety and effectiveness requirements of the
FFDC Act had no reasonable application.' 5 The court, however, qual-
ified its holding by stating that it was not concluding that all substances
were beyond the agency's reach in relation to the terminally ill.6
Rather, it was ruling that at present there exists no applicable measure
by which laetrile could be banned. 17
The Tenth Circuit's conclusion raises the issue of whether the safe
interstate commerce any new drug, unless an approval of an application is effective with respect to
such drug."
7. 399 F. Supp. 1208 (W.D. Okla. 1975). Although the action was brought as a class action,
it was not until 1977 that it was certified as one. 424 F. Supp. 105, 108 (W.D. Okla. 1977).
8. The district court remanded to the FDA the issue of whether laetrile fell within the
grandfather provisions of the FFDC Act. 424 F. Supp. at 107.
9. Id. at 106-07.
10. Id. at 107.
11. 399 F. Supp. at 1213-14. The Tenth Circuit declined to consider this issue in its decision.
582 F.2d at 1237.
Although the Tenth Circuit did not directly reach the constitutional issue, perhaps the court
did so by implication. By sufficiently narrowing the class, and by showing that there was no
known cure, the court recognized the right of cancer patients to procure laetrile. It appears that
the court engaged in a balancing of the cancer patients' interest in using laetrile with the FDA's
interest in prohibiting its use.
12. 424 F. Supp. at 107.
13. 582 F.2d at 1237.
14. Id. at 1237.
15. Id. The court of appeals, however, put several limitations on a cancer patient's access to
laetrile. First, the cancer patient must be certified by a licensed medical practitioner to be termi-
nally ill of cancer. Second, the cancer patient may only procure intravenous injections of laetrile
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and effective test of the FFDC Act is applicable to any unapproved
new drug when its use is sought by a terminally ill cancer patient. Al-
though the court of appeals recognized that there is no known cure for
cancer,' the decision does not appear to give a cancer patient carte
blanche access to any unapproved new drug. At a minimum, the deci-
sion implies that the drug must be generally recognized by experts as
nontoxic.1 9
If the substance's nontoxicity is the standard of access, what meas-
ures exist to protect the unsuspecting and vulnerable cancer patient
from being victimized by persons claiming to have some miracle cure?
The Tenth Circuit stated that the matter was a regulatory one for the
FDA.2 °
In 1973, the United States Court of Appeals for the Seventh Cir-
cuit dealt with a case similar to Rutherford. In that case, Durovic v.
Richardson,21 plaintiffs sought court approval of a new drug, krebi-
ozen, for the management and treatment of malignant tumors.22 The
FDA had earlier denied the plaintiffs' new drug application because its
evidence had failed to establish that krebiozen was both safe and effec-
tive under the requirements of the FFDC Act.23 In upholding the dis-
trict court and the FDA, the court of appeals found that krebiozen was
not sufficiently known to be recognized as safe even in the narrow sense
of being nontoxic.24 Moreover, the court concluded that the drug did
not come within the purview of the grandfather clause of the FFDC
Act.25
In light of Durovic, there is an apparent split between the Seventh
and Tenth Circuits. From the cancer patient's point of view, this di-
chotomy may create inequitable results. A cancer patient living in the
Tenth Circuit's jurisdiction could escape the FDA's prohibition against
laetrile. In contrast, those living in the Seventh Circuit's jurisdiction
would be denied access to a drug which they believe is effective in the
treatment of cancer.
This difference, however, may be reconciled by a closer examina-
tion of the facts affecting the respective decisions. In Durocvi, the court
18. Id.
19. The Tenth Circuit did not overturn the district court's finding that laetrile is a nontoxic
substance if used in proper dosage. 399 F. Supp. at 1214.
20. 582 F.2d at 1237.
21. 479 F.2d 242 (7th Cir. 1973).
22. 327 F. Supp. 386, 387 (N.D. IMI. 1971), aft'd, 479 F.2d 242 (7th Cir. 1973).
23. Id.
24. 479 F.2d at 250-251.
25. Id. at 247-49.
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upheld the FDA denial of the plaintiffs new drug application because
there was not sufficient evidence to conclude that krebiozen was non-
toxic. 26 In contrast, the plaintiffs in Rutherford did not file a new drug
application with the FDA.27 Rather, they sought to enjoin the agency
from enforcing its interstate ban on the drug.28 Moreover, the court
found laetrile to be nontoxic.2 9 Finally, the class of plaintiffs was nar-
rowed to those cancer patients certified to be terminally ill.30 Given the
factual setting of Rutherford, the Seventh Circuit might reach a similar
result on laetrile without overruling Durovic.
Today, many people are questioning orthodox approaches to the
treatment of cancer. Cancer patients, however, should be able to take
advantage of a drug which has been found to be nontoxic.31 Personal
convictions of a terminally ill cancer patient may not be easily changed
by contrary evidence. These convictions have developed in light of
conventional methods of treatment. Often orthodox methods and
treatments are painful, disfiguring, unpleasant, and involve some risk.
Understandably, cancer patients are frustrated and angered when de-
nied the right to choose a potential treatment related to their own
healths. These are persons who are terminally ill. Further treatment of
these persons should not be precluded by the FFDC Act or FDA ac-
tion, absent a sufficiently compelling basis.
Terry Horwath Bitting
26. Id. at 250-51.
27. 399 F. Supp. at 1212.
28. Id. at 1210.
29. Id. at 1214.
30. 582 F.2d at 1237.
31. Laetrile was established to be nontoxic in the FDA's records. "Laetrile--Notice of Ad-
ministrative Rule Making Hearing," 42 Fed. Reg. 10,066, 10,068 (1977).
1978]
4
Tulsa Law Review, Vol. 14 [1978], Iss. 1, Art. 9
https://digitalcommons.law.utulsa.edu/tlr/vol14/iss1/9
5Bitting: Drugs--Federal Drug Administration Ban on Laetrile Treatments for
Published by TU Law Digital Commons, 1978
